Literature DB >> 11231033

Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy.

N Hattori1, K Misu, H Koike, M Ichimura, M Nagamatsu, M Hirayama, G Sobue.   

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP), which can occur through life from childhood to old age, presents a wide variety of clinical phenotypes. We investigated the relationship between age of onset and phenotype in 124 CIDP patients. Clinical symptoms, pathologic findings and electrophysiologic features were assessed according to age at onset: juvenile, younger than 20-years-old; adult, 20 to 64; and elderly, older than 64 (total n=124). Half of the juvenile group showed subacute progression initially, while most patients in the elderly group showed chronic insidious progression (chi(2)=23.2, P<0.0001). Motor dominant neuropathy was prominent in juveniles, while sensorimotor neuropathy was frequent in the elderly group (chi(2)=27.0, P<0.0001). A relapsing and remitting course predominated in the juvenile group (chi(2)=8.50, P=0.0143). Demyelinating and axonal degenerating features in sural nerve biopsy and in nerve conduction studies were common to three age groups. The subperineurial edema was more prominent in the juvenile and adult groups (P=0.006). Functional recovery was common in all three age groups, but was least apparent in the elderly group (P=0.00062). Demyelinating features in studies of nerve conduction and biopsy specimens was common to all three age groups, and was a useful diagnostic feature. Clinical features of CIDP differ by age of onset, which is a factor to consider in diagnosis, therapy, and prognosis.

Entities:  

Mesh:

Year:  2001        PMID: 11231033     DOI: 10.1016/s0022-510x(00)00493-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  18 in total

Review 1.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy.

Authors:  David S Saperstein; Richard J Barohn
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

Review 3.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Polyneuropathy and dementia in old age: common inflammatory and vascular parameters.

Authors:  Friedrich Leblhuber; Katharina Schroecksnadel; Margit Beran-Praher; Herbert Haller; Kostja Steiner; Dietmar Fuchs
Journal:  J Neural Transm (Vienna)       Date:  2011-02-01       Impact factor: 3.575

Review 5.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

6.  Chronic inflammatory demyelinating polyradiculoneuropathy: in a remote northern Ontario hospital.

Authors:  Taryn Taylor
Journal:  Can Fam Physician       Date:  2013-04       Impact factor: 3.275

7.  A case of cauda equina syndrome in early-onset chronic inflammatory demyelinating polyneuropathy clinically similar to charcot-marie-tooth disease type 1.

Authors:  Seung Eun Lee; Seung Won Park; Sam Yeol Ha; Taek Kyun Nam
Journal:  J Korean Neurosurg Soc       Date:  2014-06-30

Review 8.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

9.  Motor-dominant chronic inflammatory demyelinating polyneuropathy.

Authors:  Akio Kimura; Takeo Sakurai; Akihiro Koumura; Megumi Yamada; Yuichi Hayashi; Yuji Tanaka; Isao Hozumi; Hiide Yoshino; Tatsuhiko Yuasa; Takashi Inuzuka
Journal:  J Neurol       Date:  2009-11-22       Impact factor: 4.849

10.  Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy.

Authors:  A Chiò; D Cocito; E Bottacchi; C Buffa; M Leone; F Plano; R Mutani; A Calvo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.